Novo Nordisk Ozempic (Semaglutide)

This product is Ozempic, a globally recognized medication for the treatment of type 2 diabetes and obesity. It was developed and patented by Novo Nordisk, a leading Danish pharmaceutical company founded in 1923 through the merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium.

Novo Nordisk maintains extensive manufacturing facilities in Denmark (notably in Bagsværd and Kalundborg) where the primary production of its insulin and GLP-1 agonists like semaglutide takes place. To meet high global demand, production also occurs in advanced facilities in the United States and France. The brand remains under the ultimate ownership of its original founding entity, specifically governed by the Novo Nordisk Foundation, ensuring it remains a cornerstone of Danish industry.